
Official statistics indicate that almost 40 million people worldwide live with HIV/AIDS.
Despite great effort, HIV-1 vaccine development has been challenging. A recent HIV vaccine trial, known as RV144, revealed that a combination of 2 vaccines protected some individuals from HIV infection.
Advertisement
Individuals in the trial that made antibodies that bound to a specific region of the HIV envelope protein had a decreased risk of HIV infection. A new study in the Journal of Clinical Investigation reveals that an individual's genotype correlates with their ability to develop immunity to HIV in response to vaccination. Sue Li and colleagues at the Fred Hutchinson Cancer Research Center sequenced genes in RV144 participants that are involved in antibody production. The authors identified single nucleotide variations in genes that encode antibody receptors, which are important for protective immunity. They found that the majority of individuals with specific variants of the FCGR2C gene were protected from HIV infection after vaccination whereas a different form of FCGR2C was not associated with protection. Their study provides important insight into the variable response of individuals in the RV144 trial.
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest AIDS/HIV News

The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.

In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.

Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.

Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.

DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.